Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis

Copyright © 2018. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 205(2019) vom: 01. Aug., Seite 130-137
1. Verfasser: Chen, Pei (VerfasserIn)
Weitere Verfasser: Li, Yingkai, Huang, Hao, Li, Yan, Huang, Xin, Chen, Zhenguang, Liu, Xiaoxi, Qiu, Li, Ou, Changyi, Huang, Zhidong, Lin, Zhongqiang, Ran, Hao, Liu, Weibin
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2019
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Corticosteroid Immunosuppressant Myasthenia gravis Myeloid dendritic cells Plasmacytoid dendritic cells pDCs/mDCs Adrenal Cortex Hormones Immunosuppressive Agents mehr... Leflunomide G162GK9U4W
Beschreibung
Zusammenfassung:Copyright © 2018. Published by Elsevier Inc.
Although it is well documented that circulating dendritic cells (DCs) have specialized features during many kinds of physiological and pathological conditions, there are few reports about the features of DCs in the peripheral blood of myasthenia gravis (MG) patients. We investigated the quantitative and component features of DCs and their implications in MG. Peripheral blood samples from different kinds of MG patients were collected and their clinical characteristics were recorded. Using flow cytometry, we distinguished circulating DC subsets [plasmacytoid DCs (pDCs) and myeloid DCs (mDCs)] and enumerated their densities in peripheral blood. Absolute numbers of circulating pDCs were significantly decreased in naïve MG patients compared with healthy controls, resulting in a markedly lower ratio of the pDC to mDC percentage in total circulating DCs (pDCs/mDCs), suggesting an imbalance in the proportions of the two main circulating DC subsets. The clinical status of MG patients was improved after drug treatment, together with increased pDCs/mDCs. In a longitudinal follow-up, we observed that circulating mDCs were significantly reduced after 1 month of therapy with a corticosteroid and immunosuppressant, resulting in recovery of pDCs/mDCs. Although the exact meaning of the proportion change in circulating DC subsets is unknown, pDCs/mDCs might reflect the balance between the autoimmune response and immune tolerance of a patient. Moreover, changes in pDCs/mDCs during treatment might be a promising marker to predict the efficacy of a specific drug used for MG patients
Beschreibung:Date Completed 20.04.2020
Date Revised 20.04.2020
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2018.10.012